Cullinan Oncology LLC (CGEM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $20.73 (-2.95%), Market cap $0.84B, 52-week low–high $5.75 ~ $16.33.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibi
Financial statements, price targets, institutional (13F) holdings and related news for Cullinan Oncology LLC are updated in real time on BlackAll Trade.
Cullinan Oncology LLC trades at $20.73 (-2.95%). Real-time quotes and charts are available on BlackAll Trade.
Cullinan Oncology LLC has a market cap of about $0.84B.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD